KRAS Q61X

Variant type

missense mutation

Location

Chromosome 17

Exon

8

Protein change

p.X61X

cDNA change

-

Genomic coordinate

Chromosome 17

FATHMM prediction

-

Variant category

I

Variant description

"The Q61 mutations occur within the switch II region of the G domain (Exon 3; Ensembl; 17579200) of KRAS, including p.Q61H, p.Q61K, p.Q61L, p.Q61P, p.Q61R, and et al.. Multiple studies have now shown that patients with tumors harboring mutations in KRAS are unlikely to benefit from anti-EGFR antibody therapy, either as monotherapy (PMID: 18316791) or in combination with chemotherapy (PMID: 19114683; 21228335; 20038723; 16618717; 20921462). Moreover, KRAS mutations are negative predictors of radiographic response to the EGFR tyrosine kinase inhibitors[for review, see (PMID: 18832458; 19349489)]. Currently, there are no direct anti-KRAS therapies available.

Variant frequence

This section displays the distribution of mutated samples and tissue types (top 5).

Accoiciated drug